AC-262536 (C09-1102-231)

AC-262536 is a selective and non-steroidal androgen receptor modulators ( SARMs ) with beneficial anabolic effects. AC-262536 exhibits potent agonist activity at the androgen receptor , with an affinity in the low nanomolar range (1-10 nM).In VitroAC-262536 dose-dependently inhibits dihydroxytestosterone (DHT)-induced proliferation of LNCaP. The effects are significant with 100 nM AC-262536 (%inhibition 47.2±12.2), and reaches a plateau with 1 μM treatment (%inhibition 50.7±7.6). Thus, AC-262536 can act as a functional antagonist in prostate cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoAC-262536 (3, 10, 30 mg/kg) reverses the luteinizing hormone (LH) spike in castrated rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley rats (200-225 g) Dosage: 3, 10 and 30 mg/kg Administration: Administered subcutaneously; once daily for 14 consecutive days Result: Significantly decreased LH levels by about 40% at the 3 mg/kg dose. The ED 50 was determined to be 2.8 mg/kg. At the 10 and 30 mg/kg doses, the effects of AC-262536 were significantly stronger than Testosterone Propionate (TP) : 1.91±0.32 ng/mL and 1.53±0.34 ng/mL vs. 3.12±0.69 ng/mL, respectively.Form:Solid. Specifications and Purity: 99%. Molecular Formula: C18H18N2O. Molecular Weight: 278.35. PubChem CID: 44512434. Isomeric SMILES: C1C[C@H]2CC(C[C@@H]1N2C3=CC=C(C4=CC=CC=C43)C#N)O.